PET vendor Positron could be headed for bankruptcy. An independent auditor has expressed "substantial doubt" that the company, which was among the pioneers of positron imaging, could continue much longer as a "going concern." The auditor's comments were
PET vendor Positron could be headed for bankruptcy. An independent auditor has expressed "substantial doubt" that the company, which was among the pioneers of positron imaging, could continue much longer as a "going concern." The auditor's comments were reported in Positron's annual report, filed March 29 with the Securities and Exchange Commission. As of Dec. 31, 2001, the company had cash and cash equivalents of $635,000 compared with cash and cash equivalents and short-term investments of $2,201,000 a year earlier. Positron has accumulated a deficit of more than $54 million since its inception in 1983, according to the auditor's statement. Only about 19 of the company's Posicam PET scanners are currently in operation, 15 of them in the U.S. The company must increase system sales to become profitable, something it has not been able to do in its 20-year history, or obtain additional capital, according to the auditor.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.